Dapsone Gel Recalled Nationwide for Crystallization
Viona Pharmaceuticals is recalling Dapsone Gel 7.5% nationwide due to crystallization detected in multiple lots. Patients should contact their pharmacy or healthcare provider for guidance.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is a Class II drug recall with no reported illnesses or injuries. The identified defect is crystallization, a product quality issue. The firm voluntarily initiated the recall. Per the severity rubric, this qualifies as Moderate because it represents a voluntary precautionary recall without reported harm.
Plain-English summary
Viona Pharmaceuticals Inc. is recalling Dapsone Gel 7.5% (60 g) distributed nationwide in the United States. The recall affects seven lots with expiration dates ranging from February 2026 to August 2026, totaling 23,304 packs.
The firm initiated this voluntary recall in response to crystallization detected in the product. The FDA classified this as a Class II recall.
Patients currently using affected lots should contact their pharmacy or healthcare provider for guidance on next steps. Do not discontinue use of the medication without consulting a healthcare professional.
The recalled product
- Product
- DAPSONE (DAPSONE)
- Brand
- DAPSONE
- Manufacturer
- VIONA PHARMACEUTICALS INC
- Category
- Drug — Topical
- Hazard
- crystallization
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (11)
- Lots T400513
- Exp Date 02/2026
- T400807
- Exp Date 03/2026
- T401152
- Exp Date 06/2026
- T401303
- Exp Date 07/2026
- T401304
- T401399
- Exp Date 07/2026 & T401696 Exp Date 08/2026.
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · DAPSONE
- HighDapsone Topical Gel Recalled Due to Crystallization Defect
FDA (Drugs) · 2025-01-08
- ModerateDapsone Gel 7.5% recalled nationwide due to crystallization
FDA (Drugs) · 2024-11-13
- ModeratePrescription Dapsone Gel 7.5% Recalled Due to Crystallization
FDA (Drugs) · 2024-10-23
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereErythromycin Tablets Recalled for Impurity Above Acceptable Limits
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- ModeratePrimidone Tablets Recalled Due to API Cross-Contamination
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27